Loading...
CTIC logo

CTI BioPharma Corp.NasdaqCM:CTIC Stok Raporu

Piyasa Değeri US$1.2b
Hisse Fiyatı
n/a
Adil Değerim
Kullanılamıyor
1Y66.2%
7D-0.1%
1D
Portföy Değeri
​
Görünüm

CTI BioPharma Corp.

NasdaqCM:CTIC Stok Raporu

Piyasa değeri: US$1.2b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

CTI BioPharma (CTIC) Hisse Özeti

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. Daha fazla detay

Ödüller

Kazançların yılda 59.97% oranında artması öngörülüyor

Risk Analizi

Negatif hissedar öz sermayesi

Son 3 ayda hisse senedi fiyatı US piyasasına kıyasla oldukça dalgalı

1 yıldan az nakit akışı var

Hissedarlar geçen yıl sulandırıldı


CTIC Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

CTI BioPharma Corp. Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti CTI BioPharma
Tarihsel hisse senedi fiyatları
Güncel Hisse FiyatıUS$9.09
52 Haftanın En Yüksek SeviyesiUS$9.10
52 Haftanın En Düşük SeviyesiUS$4.01
Beta0.83
1 Aylık Değişim0.44%
3 Aylık Değişim112.38%
1 Yıllık Değişim66.18%
3 Yıllık Değişim690.43%
5 Yıllık Değişim73.47%
Halka arzdan bu yana değişim-99.99%

Son Haberler & Güncellemeler

Seeking Alpha • Aug 17

CTI BioPharma: Reiterating Target Price Of $17 After Successful VONJO Launch

CTIC announced its 2Q 2022 results on 8 August. With booked revenues coming in at $12.3 million for the quarter, revenues were above Street expectations. In my view, the 26% share price decline since the results is a reaction to BVF Partners (a major equity holder of the company) selling shares. I view this decline as a major buying opportunity. I believe the market totally ignored the $8.2 million in accounts receivables reported by the company. The CFO’s repeated statements that CTIC has sufficient cash to meet its financial obligations through 2023 is a major clue that further dilution is not likely. I am maintaining my target price of $17. I will continue to hold CTIC until a buyout or my target is achieved in the next 1.5 to 3.5 years. Background As an update to my previous article on CTI BioPharma (CTIC), where I recommended this stock as a "Strong Buy" and a $17 price target, CTIC’s first complete quarter of sales in its history was greeted with enthusiasm by Wall Street analysts. Most analysts reiterated their “Buy” ratings and maintained or revised their price targets higher. While the launch of VONJO (CTIC's only approved drug for the treatment of adults with intermediate or high-risk post-polycythemia vera or post-essential thrombocythemia) was viewed as being successful by the street (and management), the $12.3 million in net sales reported by the company was only in line with Inrebic (BMY) sales in the first quarter after its launch in 4Q 2019. To a certain extent, traders were taking profits and viewed the $12.3 million revenue figure with disappointment, punishing the stock by -22.9% at one point on Tuesday, 9th April 2022, before the stock recovered to close -11.8% on that day. Since then, however, CTIC has lost about 26% of its value from its highs of $7.56 prior to the earnings release, coming back to about the level where I recommended the stock back on May 04, 2022. Another factor impacting the price dynamic was the fact that BVF Partners sold 8.5 million shares in the company on August 9, 2022 (according to BVF Partners' Form 4 filing). The market took this as a major equity holder selling stock and perhaps losing some faith in the growth prospects of the company. Why I am maintaining my DCF Valuation In my view, the market completely ignored the $8.2 million in Accounts Receivables reported by the company in 2Q.2022 (see pp. 4 of CTIC's 2Q.2022 10Q Filing). If we add this to the top line reported revenue figure, VONJO sales for the quarter would have been $20.5 million – or 70% higher than Inrebic sales at the same stage of Inrebic’s commercial launch. VONJO is off to a great start and confirms for me that VONJO is highly differentiated from Incyte Corporation's (INCY) JAKAFI. As I stated in my previous article, my own interviews with hematologists indicated that they have been waiting for VONJO to come to market for the 7,000 patients in the United States that suffer from severe thrombocytopenia (i.e., blood platelet counts under 50 x10^9 /L). Management’s repeated comments that there is a 60 / 40 split in hospital / community prescribers is also very bullish, as cancer drugs normally get acceptance in the hospital setting before a slow ramp up into the community setting. That is not the case for VONJO. While we may never know how many patient lives are impacted by CTIC (unless the company reveals it – which their CEO has refused to do in the past), we can model and benchmark this additional sales information to inform our unit economics going forward. At a wholesale price of $19,500, the $20.5 million in sales represents 350 prescriptions per month ($20.5 million / $19,500 / 3) in the quarter. It will be useful for us to track this number in order to understand CTIC’s market share gain over time. At 350 prescriptions (assuming 1 prescription per patient), CTIC’s market share of the 7,000 patients in the United States that suffer from severe thrombocytopenia now stands at 5%. Again, that is an excellent start. My expectation in my previous DCF model was a quick ramp-up to 1,750 patients, or a 25% market share by the end of 2022 (due to the unmet medical need). That is likely not going to happen. At a run rate of 350 patients per quarter, we are looking at 1,050 patients by the end of 2022 (a 15% market share). I do, however, think that in 2023, and beyond, VONJO is more than capable of taking a 30% market share in 2023, and a 50% market share in 2024, as CTIC continues to educate specialists on further positive trial data. See my slightly revised unit economics figures below: Table 1: CTIC’s Unit Economics Unit Economics 2022 2023 2024 2025 2026 2027 Old Model (May 2022) 1,750 2,333 3,500 3605 3,713 3,825 Old Model Revs ($ million) $209.6 $387.5 $604.6 $647.6 $693.7 $743.1 New Model(August 2022) 1,050 2,333 3,500 3,605 3,713 3,825 New Model Revs ($ million) $125.8 same same same same same Maintaining my Cost Forecast for CTIC While CTIC missed the street expectations on the bottom line by a penny, I was actually quite encouraged by management’s cost control. Total operating and non-operating expenses came in at $34.983 million, much lower than my run rate calculations of $53 million in my DCF model that you can see in my previous article. The $18 million difference was due partially to the fact that CTIC has not yet paid the $10.3 million owed to Takeda, opting instead to drag out this payment until March 15, 2023; and the $25 million payment to SBIO + low single-digit royalties to SBIO that continues to show in CTIC’s books under Intangible Assets, but will at some point move to the income statement. I am, therefore, maintaining my conservative cost forecasts for CTIC. BVF Sale was 18.8% of their overall holdings and likely motivated by fund dynamics The elephant in the room, of course, is the stock sale by BVF on August 9. While the retail comment boards were full of criticism about the BVF Partners’ stock sale, according to BVF’ Form 13F and Form 13D filings and CTIC's Form 8K filing, it looks like BVF sold 8.5 million shares out of its total holdings of 45.3 million shares of CTIC, or 18.8% of its holdings.
Seeking Alpha • Aug 08

CTI BioPharma GAAP EPS of -$0.21 misses by $0.01, revenue of $12.33M beats by $3.23M

CTI BioPharma press release (NASDAQ:CTIC): Q2 GAAP EPS of -$0.21 misses by $0.01. Revenue of $12.33M beats by $3.23M.
Seeking Alpha • Jul 19

CTI BioPharma: Approval Is Great, Now There's The Follow Through

CTI BioPharma's Pacritinib has been conditionally approved. It has critical differentiations with Incyte's Jakafi. While the potential is huge, cash and some data points are worrying signs. CTI BioPharma Corp. (CTIC) was granted accelerated approval of VONJO or pacritinib for the treatment of adults with myelofibrosis ("MF") with a platelet count below 50 times 10 to 9 per liter. This approval was based on the Phase III PERSIST-2 trial, a study that enrolled myelofibrosis patients with platelet counts less than or equal to 100 times 10 to 9 per liter, making it the only randomized controlled study specifically designed to recruit the cytopenic myelofibrosis population, that is patients with thrombocytopenia and anemia. Announcing the approval, the company CEO said: In the U.S., there are approximately 21,000 patients with myelofibrosis, two-thirds of which have cytopenias (thrombocytopenia or anemia), commonly resulting from the toxicity of other approved therapies. Severe thrombocytopenia, defined as a blood platelet count below 50 × 109/L, occurs in one-third of the overall myelofibrosis population, and has a particularly poor prognosis. With the approval of VONJO, we are excited to now be able to offer a new therapy that is specifically approved for patients with cytopenic myelofibrosis. We are fully funded for commercial launch, following our debt and royalty transactions with DRI, and we look forward to providing VONJO, the potential best-in-class therapy for cytopenic myelofibrosis patients, to patients within 10 days. Incyte's (INCY) Jakafi is also approved for MF patients, though it is approved for patients with a higher platelet count compared to VONJO. Jakafi earned $2.4bn last year, and while exact figures for the MF indication are not known to me, I am guessing that VONJO is looking at a huge market, running into billions of dollars. There are 21,000 MF patients in the U.S., and about a third of them have low platelets where no other therapy is approved. VONJO is priced at $19,500 per month, or $240,000 per year. That is an effective market of nearly $2bn in the U.S. alone. Jakafi's activity against both JAK1 and JAK2 versus pacritinib's focus on JAK2 only, mostly avoiding the problematic JAK1 pathway, gives it an edge. Like I discussed earlier, high-dose Jakafi at 20mg is effective but toxic, which is where VONJO has its advantage. As company management recently said: The physician -- the frustration of physicians, as we've said previously, is the dissatisfaction with low-dose rux. It's very common, particularly in the community practice because dose -- the dose has to be altered based on the toxicities seen, and it's -- it can be a complicated management scenario. What the feedback -- some of the feedback we've got from physicians has been the attractiveness of VONJO is that the drug can be given at full dose without the need for large numbers of dose modifications. CTIC was also lucky to be able to get VONJO included in NCCN guidelines, which is the largest network of comprehensive cancer treatment centers in the US. Inclusion here means wider propagation and a guarantee of higher sales because most oncologists in the U.S. - even elsewhere - look to the NCCN guidelines for latest updates on standard practices. Although the company still has to complete the PACIFICA trial (topline in 2025) for full approval, things are going well for VONJO so far. Last month, the company presented PERSIST 1 and 2 data at the European Hematology Association ((EHA)) 2022 Congress. According to Seeking Alpha: The analysis indicated a similar incidence of bleeding events as well as overall and fatal adverse events for pacritinib and ruxolitinib. Notably, the cardiac events were more common in patients who received pacritinib, CTIC said, attributing the difference mainly to higher rates of grade 1 peripheral edema on the therapy.
Seeking Alpha • Jul 07

CTI BioPharma initiated at outperform at Cowen on potential for Vonjo for myelofibrosis

Cowen has initiated CTI Biopharma (NASDAQ:CTIC) with an outperform rating citing the growth potential of Vonjo (pacritinib), which was approved in February for thrombocytopenic myelofibrosis. Shares are up 14% in Thursday afternoon trading. The firm has a $10 price target (~67% upside based on Wednesday's close). Analyst Boris Peaker said that one of the advantages of Vonjo over current treatments is that as a JAK2/IRAK1 inhibitor, it appears to be missing JAK inhibitor treatment-emergent thrombocytopenia and is also effective no matter the baseline platelet count. He added that Vonjo is approved for patients with very low platelet counts and the National Comprehensive Cancer Network guidelines call for the therapy's use in a second-line setting, both developments that support broader use. Incyte's (INCY) Jakafi (ruxolitinib) is a competitor to Vonjo, though it is approved for patients with a higher platelet count compared to Vonjo. Peaker is estimating $1B in peak sales, though the amount could be higher due to off-label use. Vonjo can achieve a 55% market share of U.S. patients by 2027, according to Seeking Alpha contributor Nizar Assanie.

Recent updates

Seeking Alpha • Aug 17

CTI BioPharma: Reiterating Target Price Of $17 After Successful VONJO Launch

CTIC announced its 2Q 2022 results on 8 August. With booked revenues coming in at $12.3 million for the quarter, revenues were above Street expectations. In my view, the 26% share price decline since the results is a reaction to BVF Partners (a major equity holder of the company) selling shares. I view this decline as a major buying opportunity. I believe the market totally ignored the $8.2 million in accounts receivables reported by the company. The CFO’s repeated statements that CTIC has sufficient cash to meet its financial obligations through 2023 is a major clue that further dilution is not likely. I am maintaining my target price of $17. I will continue to hold CTIC until a buyout or my target is achieved in the next 1.5 to 3.5 years. Background As an update to my previous article on CTI BioPharma (CTIC), where I recommended this stock as a "Strong Buy" and a $17 price target, CTIC’s first complete quarter of sales in its history was greeted with enthusiasm by Wall Street analysts. Most analysts reiterated their “Buy” ratings and maintained or revised their price targets higher. While the launch of VONJO (CTIC's only approved drug for the treatment of adults with intermediate or high-risk post-polycythemia vera or post-essential thrombocythemia) was viewed as being successful by the street (and management), the $12.3 million in net sales reported by the company was only in line with Inrebic (BMY) sales in the first quarter after its launch in 4Q 2019. To a certain extent, traders were taking profits and viewed the $12.3 million revenue figure with disappointment, punishing the stock by -22.9% at one point on Tuesday, 9th April 2022, before the stock recovered to close -11.8% on that day. Since then, however, CTIC has lost about 26% of its value from its highs of $7.56 prior to the earnings release, coming back to about the level where I recommended the stock back on May 04, 2022. Another factor impacting the price dynamic was the fact that BVF Partners sold 8.5 million shares in the company on August 9, 2022 (according to BVF Partners' Form 4 filing). The market took this as a major equity holder selling stock and perhaps losing some faith in the growth prospects of the company. Why I am maintaining my DCF Valuation In my view, the market completely ignored the $8.2 million in Accounts Receivables reported by the company in 2Q.2022 (see pp. 4 of CTIC's 2Q.2022 10Q Filing). If we add this to the top line reported revenue figure, VONJO sales for the quarter would have been $20.5 million – or 70% higher than Inrebic sales at the same stage of Inrebic’s commercial launch. VONJO is off to a great start and confirms for me that VONJO is highly differentiated from Incyte Corporation's (INCY) JAKAFI. As I stated in my previous article, my own interviews with hematologists indicated that they have been waiting for VONJO to come to market for the 7,000 patients in the United States that suffer from severe thrombocytopenia (i.e., blood platelet counts under 50 x10^9 /L). Management’s repeated comments that there is a 60 / 40 split in hospital / community prescribers is also very bullish, as cancer drugs normally get acceptance in the hospital setting before a slow ramp up into the community setting. That is not the case for VONJO. While we may never know how many patient lives are impacted by CTIC (unless the company reveals it – which their CEO has refused to do in the past), we can model and benchmark this additional sales information to inform our unit economics going forward. At a wholesale price of $19,500, the $20.5 million in sales represents 350 prescriptions per month ($20.5 million / $19,500 / 3) in the quarter. It will be useful for us to track this number in order to understand CTIC’s market share gain over time. At 350 prescriptions (assuming 1 prescription per patient), CTIC’s market share of the 7,000 patients in the United States that suffer from severe thrombocytopenia now stands at 5%. Again, that is an excellent start. My expectation in my previous DCF model was a quick ramp-up to 1,750 patients, or a 25% market share by the end of 2022 (due to the unmet medical need). That is likely not going to happen. At a run rate of 350 patients per quarter, we are looking at 1,050 patients by the end of 2022 (a 15% market share). I do, however, think that in 2023, and beyond, VONJO is more than capable of taking a 30% market share in 2023, and a 50% market share in 2024, as CTIC continues to educate specialists on further positive trial data. See my slightly revised unit economics figures below: Table 1: CTIC’s Unit Economics Unit Economics 2022 2023 2024 2025 2026 2027 Old Model (May 2022) 1,750 2,333 3,500 3605 3,713 3,825 Old Model Revs ($ million) $209.6 $387.5 $604.6 $647.6 $693.7 $743.1 New Model(August 2022) 1,050 2,333 3,500 3,605 3,713 3,825 New Model Revs ($ million) $125.8 same same same same same Maintaining my Cost Forecast for CTIC While CTIC missed the street expectations on the bottom line by a penny, I was actually quite encouraged by management’s cost control. Total operating and non-operating expenses came in at $34.983 million, much lower than my run rate calculations of $53 million in my DCF model that you can see in my previous article. The $18 million difference was due partially to the fact that CTIC has not yet paid the $10.3 million owed to Takeda, opting instead to drag out this payment until March 15, 2023; and the $25 million payment to SBIO + low single-digit royalties to SBIO that continues to show in CTIC’s books under Intangible Assets, but will at some point move to the income statement. I am, therefore, maintaining my conservative cost forecasts for CTIC. BVF Sale was 18.8% of their overall holdings and likely motivated by fund dynamics The elephant in the room, of course, is the stock sale by BVF on August 9. While the retail comment boards were full of criticism about the BVF Partners’ stock sale, according to BVF’ Form 13F and Form 13D filings and CTIC's Form 8K filing, it looks like BVF sold 8.5 million shares out of its total holdings of 45.3 million shares of CTIC, or 18.8% of its holdings.
Seeking Alpha • Aug 08

CTI BioPharma GAAP EPS of -$0.21 misses by $0.01, revenue of $12.33M beats by $3.23M

CTI BioPharma press release (NASDAQ:CTIC): Q2 GAAP EPS of -$0.21 misses by $0.01. Revenue of $12.33M beats by $3.23M.
Seeking Alpha • Jul 19

CTI BioPharma: Approval Is Great, Now There's The Follow Through

CTI BioPharma's Pacritinib has been conditionally approved. It has critical differentiations with Incyte's Jakafi. While the potential is huge, cash and some data points are worrying signs. CTI BioPharma Corp. (CTIC) was granted accelerated approval of VONJO or pacritinib for the treatment of adults with myelofibrosis ("MF") with a platelet count below 50 times 10 to 9 per liter. This approval was based on the Phase III PERSIST-2 trial, a study that enrolled myelofibrosis patients with platelet counts less than or equal to 100 times 10 to 9 per liter, making it the only randomized controlled study specifically designed to recruit the cytopenic myelofibrosis population, that is patients with thrombocytopenia and anemia. Announcing the approval, the company CEO said: In the U.S., there are approximately 21,000 patients with myelofibrosis, two-thirds of which have cytopenias (thrombocytopenia or anemia), commonly resulting from the toxicity of other approved therapies. Severe thrombocytopenia, defined as a blood platelet count below 50 × 109/L, occurs in one-third of the overall myelofibrosis population, and has a particularly poor prognosis. With the approval of VONJO, we are excited to now be able to offer a new therapy that is specifically approved for patients with cytopenic myelofibrosis. We are fully funded for commercial launch, following our debt and royalty transactions with DRI, and we look forward to providing VONJO, the potential best-in-class therapy for cytopenic myelofibrosis patients, to patients within 10 days. Incyte's (INCY) Jakafi is also approved for MF patients, though it is approved for patients with a higher platelet count compared to VONJO. Jakafi earned $2.4bn last year, and while exact figures for the MF indication are not known to me, I am guessing that VONJO is looking at a huge market, running into billions of dollars. There are 21,000 MF patients in the U.S., and about a third of them have low platelets where no other therapy is approved. VONJO is priced at $19,500 per month, or $240,000 per year. That is an effective market of nearly $2bn in the U.S. alone. Jakafi's activity against both JAK1 and JAK2 versus pacritinib's focus on JAK2 only, mostly avoiding the problematic JAK1 pathway, gives it an edge. Like I discussed earlier, high-dose Jakafi at 20mg is effective but toxic, which is where VONJO has its advantage. As company management recently said: The physician -- the frustration of physicians, as we've said previously, is the dissatisfaction with low-dose rux. It's very common, particularly in the community practice because dose -- the dose has to be altered based on the toxicities seen, and it's -- it can be a complicated management scenario. What the feedback -- some of the feedback we've got from physicians has been the attractiveness of VONJO is that the drug can be given at full dose without the need for large numbers of dose modifications. CTIC was also lucky to be able to get VONJO included in NCCN guidelines, which is the largest network of comprehensive cancer treatment centers in the US. Inclusion here means wider propagation and a guarantee of higher sales because most oncologists in the U.S. - even elsewhere - look to the NCCN guidelines for latest updates on standard practices. Although the company still has to complete the PACIFICA trial (topline in 2025) for full approval, things are going well for VONJO so far. Last month, the company presented PERSIST 1 and 2 data at the European Hematology Association ((EHA)) 2022 Congress. According to Seeking Alpha: The analysis indicated a similar incidence of bleeding events as well as overall and fatal adverse events for pacritinib and ruxolitinib. Notably, the cardiac events were more common in patients who received pacritinib, CTIC said, attributing the difference mainly to higher rates of grade 1 peripheral edema on the therapy.
Seeking Alpha • Jul 07

CTI BioPharma initiated at outperform at Cowen on potential for Vonjo for myelofibrosis

Cowen has initiated CTI Biopharma (NASDAQ:CTIC) with an outperform rating citing the growth potential of Vonjo (pacritinib), which was approved in February for thrombocytopenic myelofibrosis. Shares are up 14% in Thursday afternoon trading. The firm has a $10 price target (~67% upside based on Wednesday's close). Analyst Boris Peaker said that one of the advantages of Vonjo over current treatments is that as a JAK2/IRAK1 inhibitor, it appears to be missing JAK inhibitor treatment-emergent thrombocytopenia and is also effective no matter the baseline platelet count. He added that Vonjo is approved for patients with very low platelet counts and the National Comprehensive Cancer Network guidelines call for the therapy's use in a second-line setting, both developments that support broader use. Incyte's (INCY) Jakafi (ruxolitinib) is a competitor to Vonjo, though it is approved for patients with a higher platelet count compared to Vonjo. Peaker is estimating $1B in peak sales, though the amount could be higher due to off-label use. Vonjo can achieve a 55% market share of U.S. patients by 2027, according to Seeking Alpha contributor Nizar Assanie.
Seeking Alpha • May 04

CTI BioPharma - 3.2x Potential Upside On A De-Risked Asset

CTIC is undervalued and a strong buy for new investors. The current share price of ~$5.63 does not reflect the potential of outsized returns to patient, long-term investors. Under conservative assumptions, my DCF model shows the equity value of CTIC at $17 per fully diluted share, an ~3.2x ROI from current levels. VONJO's closest competitor (INCY's JAKAFI) is not indicated for blood platelet counts under 50 x10^9 /L. This makes VONJO a highly differentiated product. My unit economics assume sales only in the U.S., VONJO achieving 55% market share of U.S. patients only in 2027, and only 20% of the patient population being first-line patients.
Seeking Alpha • Apr 11

CTI BioPharma Corp.: Pacritinib Approval, Downgrade To A Sell Rating

FDA approved Pacritinib on Feb 28th, and the stock has appreciated more than 150%. However, the risk-reward has deteriorated significantly since our last article. The company does not have any more short-term catalysts, and considering that Pacritinib is an encumbered asset (deal with DRI), we do not think M&A is a likely scenario. We are downgrading to a sell as we expect selling pressure to abound from fund managers trying to short the launch. Commercialization remains to be uncertain, and dilution may be a potential risk.
Seeking Alpha • Mar 01

CTI BioPharma: A Speculative Buy Into The PDUFA Date

We are initiating with CTI BioPharma with a buy rating with a TP of USD 7.6 if pacritinib is approved. We opine that CTI BioPharma's current set-up represents an attractive risk-reward scenario with ~50% potential downside (around cash value of $1/share) and ~320% potential upside (bull case $7.6 if approved). We like the clinical data that pacritinib has produced, targeting a niche MF patient population where Jakafi can't be used. FDA delay is likely a minor issue, and we expect the drug to receive the FDA's stamp of approval soon on Feb. 28th.
Seeking Alpha • Dec 24

CTI BioPharma: Long And Troubled History, Finally Approaching Approval

CTIC's Pacritinib approval was delayed by three months on what appears to be a major safety data amendment. Pacritinib has a lot of baggage. The new PDUFA date is February 28.

Hissedar Getirileri

CTICUS BiotechsUS Pazar
7D-0.1%2.9%2.5%
1Y66.2%33.0%26.4%

Getiri vs. Endüstri: CTIC geçen yıl % 33 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: CTIC geçen yıl % 26.4 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is CTIC's price volatile compared to industry and market?
CTIC volatility
CTIC Average Weekly Movement25.3%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.1%

İstikrarlı Hisse Senedi Fiyatı: CTIC hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.

Zaman İçindeki Volatilite: CTIC 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 15% dan 25% a yükseldi.

Şirket Hakkında

KurulduÇalışanlarCEOWeb sitesi
1991128Adam Craigwww.ctibiopharma.com

CTI BioPharma Corp. Temel Bilgiler Özeti

CTI BioPharma'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
CTIC temel i̇stati̇sti̇kler
Piyasa değeriUS$1.20b
Kazançlar(TTM)-US$69.24m
Gelir(TTM)US$75.77m
15.8x
P/S Oranı
-17.3x
F/K Oranı

CTIC aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
CTIC gelir tablosu (TTM)
GelirUS$75.77m
Gelir MaliyetiUS$4.46m
Brüt KârUS$71.31m
Diğer GiderlerUS$140.55m
Kazançlar-US$69.24m

Son Raporlanan Kazançlar

Mar 31, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)-0.53
Brüt Marj94.11%
Net Kâr Marjı-91.38%
Borç/Özkaynak Oranı-459.4%

CTIC uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2023/06/28 23:34
Gün Sonu Hisse Fiyatı2023/06/23 00:00
Kazançlar2023/03/31
Yıllık Kazançlar2022/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

CTI BioPharma Corp. 16 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Kimberly LeeBrean Capital Historical (Janney Montgomery)
Leah Rush CannBrookline Capital Markets
null nullBTIG